

Curriculum Vitae:



Prof. Dr. Carsten Bokemeyer

Present Ranks: Director
Department of Oncology, Hematology, Bone Marrow
Transplantation with section Pneumology
Department of Medicine
University Hospital Hamburg-Eppendorf
Hamburg, Germany

Director University Cancer Center Hamburg
University Hospital Hamburg-Eppendorf
Hamburg, Germany

Education:

1989 M. D. / University of Hannover Medical School, Hannover,
Germany
1989 FMGEMS
1989-1995 Internal Medicine Internship / Residency
University of Hannover Medical School
Hannover, Germany
1995-2004 Faculty Member
Department of Internal Medicine
Division of Hematology / Oncology / Immunology / Rheumatology
University of Tuebingen Medical Center
Tuebingen, Germany

Academic Appointments:

1996 "Habilitation" (Postdoctoral lecturing qualification)
Department of Internal Medicine
Medical School Hannover, Germany
2000 Nominated for C3 position as Professor of Medicine at Muenster
University, Germany
2000 Associate Professor of Medicine at Tuebingen University

- 2004 Appointed Professor of Medicine, Director of Division of Oncology / Hematology with sections Bone Marrow Transplantation and Pneumology
- 2007 Nominated Director University Cancer Center Hamburg

Specialty Board Status:

- 1993 Certification – European Society for Medical Oncology
- 1995 Certification – German Board of Internal Medicine
- 1997 Certification – German Board of Internal Medicine: Hematology-Medical Oncology
- 2000 Certification – Quality Management in Medicine

Professional Societies:

- 1991-present German Cancer Society (DKG)
- 1991-present Wilsede School of Oncology
- 1991-present European Society of Medical Oncology (ESMO)
- 1995-present American Society of Clinical Oncology (ASCO)
- 1995-present German Society of Hematology / Oncology (DGHO)
- 1998-present German Association for Bone Marrow and Blood Stem Cell Transplantation (DAGKBT)

Honors /Awards:

- Undergraduate
 - Member of the “Studienstiftung des deutschen Volkes” (German Academic Scholarship Fund)
 - Award of the Ministry of Science for “Outstanding Student Achievements in Medicine”
- Graduate
 - 2000 National Award of the German Cancer Society
 - 2000 Award for Experimentel Urological Reseach German Society of Urology
 - 2001 Award of the Baden-Wuerttembergische Cancer Society
 - 2001 Award of the German Society for Clinical Pharmacology
 - 2002 Scientific Award for Medical Oncology (AIO)
 - 2006 Award of the University of Heidelberg (Anita- und Cuno-Wieland-Preis)

Committees:

1997-2004	Member of the Research Advisory Committee of the University of Tuebingen
2000-2004	Founding member of the Interdisciplinary Center for GI-cancer at Tuebingen University
2001-2004	Founding member of the Interdisciplinary Center for Soft Tissue Sarcomas at Tuebingen University
2002-present	Chairman of the ESMO Examination Committee for Medical Oncology
2002-present	Board member of the German Society for Haematology and Oncology
2005-present	Board member of the German Cancer Society (DKG)
2005-present	Board member of the Cancer Society of Hamburg

Clinical Trials:

Experience in GCP-conform conduct of clinical studies as participant and investigator for more than 15 years

Publications:

Editor of 10 books on oncology/supportive care

Author/coauthor 87 book chapters on Oncology/Hematology/Supportive Care

Author/coauthor of 329 original publications / reviews

10 most important publications

1. Schwab M, Zanger UM, Marx C, Schaeffler E, Klein K, Dippon J, Kerb R, Bliedernicht J, Fischer J, Hofmann U, **Bokemeyer C**, Eichelbaum M: Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. *J Clin Oncol*, Mar 2008 - Epub ahead of print.
2. Hartmann JT, Gauler T, Metzner B, Gerl A, Casper J, Rick O, Horger M, Schleicher J, Derigs G, Mayer-Steinacker R, Beyer J, Kuczyk MA, **Bokemeyer C**; German Testicular Cancer Study Group: Phase I/II study of sequential dose-intensified ifosfamide, cisplatin and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group. *J Clin Oncol* 25: 5742-2747, 2007.
3. Schittenhelm MM, Shiraga S, Schroeder A, Corbin AS, Griffith D, Lee FY, **Bokemeyer C**, Deininger MW, Druker BJ, Heinrich MC: Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. *Cancer Res* 66: 473-481, 2006.

4. Honecker F, Stoop H, de Krijger R, Lau C, Castrillon D, Oosterhuis J, **Bokemeyer C**, Looijenga LHJ: Pathobiological implications of the expression of markers of testicular carcinoma in situ by fetal germ cells. *Am J Pathol* 203:849-857, 2004.
5. Kollmannsberger C, Beyer J, Liersch R, Schoeffski P, Metzner B, Rick O, Hartmann JT, Stengele K, Hohloch K, Spott C, Kanz L, **Bokemeyer C**: Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group (GTCSG). *J Clin Oncol* 22:108-114, 2004.
6. Schmoll HJ, Kollmannsberger C, Metzner B, Hartmann JT, Schleucher N, Schöffski P, Schleicher J, Rick O, Beyer J, Hossfeld DK, Kanz L, Berdel WE, Andreesen R, **Bokemeyer C**: Long-term results of first-line sequential high-dose VIP-chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German testicular study group. *J Clin Oncol* 21:4083-4091, 2003.
7. **Bokemeyer C**, Nichols C, Droz JP, Schmoll E, Horwich A, Gerl A, Fossa SD, Beyer J, Pont J, Einhorn L, Hartmann JT: Extragonadal germ cell tumors of the mediastinum and retroperitoneum - results from an international analysis. *J Clin Oncol* 20:1864-1873, 2002.
8. Mayer F, Gillis AJM, Dinjens W, Oosterhuis JW, **Bokemeyer C**, Looijenga LHJ: Microsatellite instability of germ cell tumors is associated with resistance to systemic treatment. *Cancer Res* 62:2758-2760, 2002.
9. **C. Bokemeyer**, A. J. M. Gillis, K. Pompe, F. Mayer, B. Metzner, N. Schleucher, J. schleicher, G. Pflugrad-Jauch, J. Oosterhuis, L. Kanz, and L. Looijenga. Clinical impact of germ cell tumor cells in apheresis products of patients receiving high-dose chemotherapy. *J Clin Oncol* 19 (12):3029-3036, 2001
10. J. T. Hartmann, S. D. Fossa, C. Nichols, J. P. Droz, A. Horwich, A. Gerl, J. Beyer, J. Pont, K. Fizazi, H. Hecker, L. Kanz, L. Einhorn, and **C. Bokemeyer**. Incidence of metachronous testicular cancer in patients with extragonadal germ cell tumors. *J Natl.Cancer Inst.* 93 (22):1733-1738, 2001.
11. J. T. Hartmann, C. R. Nichols, J. P. Droz, A. Horwich, A. Gerl, S. D. Fossa, J. Beyer, J. Pont, K. Fizazi, L. Einhorn, L. Kanz, and **C. Bokemeyer**. Hematologic disorders associated with primary mediastinal nonseminomatous germ cell tumors. *J Natl.Cancer Inst.* 92 (1):54-61, 2000.
12. **C. Bokemeyer**, C. Kollmannsberger, C. Meisner, A. Harstrick, J. Beyer, B. Metzner, J. T. Hartmann, H. J. Schmoll, L. Einhorn, L. Kanz, and C. Nichols. First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis. *J Clin Oncol* 17 (11):3450-3456, 1999.
13. **C. Bokemeyer**, P. Nowak, A. Haupt, B. Metzner, H. Kohne, J. T. Hartmann, L. Kanz, and H. J. Schmoll. Treatment of brain metastases in patients with testicular cancer. *J Clin Oncol* 15 (4):1449-1454, 1997.
14. **C. Bokemeyer**, C. C. Berger, M. A. Kuczyk, and H. J. Schmoll. Evaluation of long-term toxicity after chemotherapy for testicular cancer. *J Clin Oncol* 14 (11):2923-

2932, 1996..